ArticleInvestigational new drugs2013

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.

S Betty Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.